TH-302: Updated Phase I/II data
Threshold reported updated data from the ongoing Phase I/II TH-CR-402 trial evaluating IV TH-302 in combination with Gemzar gemcitabine, Alimta pemetrexed or Taxotere docetaxel in patients with advanced solid tumors. In 43 evaluable patients with advanced or metastatic pancreatic cancer, 340 mg/m 2 TH-302 plus Gemzar produced 1 complete response, 5 partial responses (PR) and 14 cases of stable disease (SD), while 240 mg/m 2 TH-302 plus Gemzar produced 13 cases of SD. Median progression-free survival (PFS) and overall survival (OS) were 6.4 and 11.4 months, respectively. In 32 evaluable patients with non-small cell lung cancer (NSCLC), TH-302 plus Taxotere or Alimta produced 8 PRs and 14 cases of SD. Median PFS was 4.2 months. In 13 evaluable patients with castration-resistant prostate cancer (CRPC), TH-302 plus Taxotere produced 3 PRs and 9 cases of SD. Additionally, 73% of 15 evaluable patients with CRPC achieved a >50% reduction from baseline in PSA levels. Data were presented at the European Society for Medical Oncology meeting in Milan. ...